Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium, Inc. (NASDAQ: EQ) presented positive results from its EQUATE study at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. The study analyzed the use of itolizumab combined with systemic corticosteroids in treating acute graft-versus-host disease (aGVHD). The findings showed significant clinical responses and improved progression-free survival rates over one year. Itolizumab demonstrated a favorable safety profile and may reduce corticosteroid usage by 99% within six months. Following this data, the pivotal Phase 3 EQUATOR study of itolizumab is underway, targeting first-line treatment of aGVHD, a condition with no approved first-line therapies.
Equillium, Inc. (Nasdaq: EQ) reported a cash balance of $71.0 million at the end of 2022, ensuring funding through 2025. The company acquired Bioniz Therapeutics, enhancing its pipeline with EQ101 and EQ102, both in clinical trials.
Equillium received $26.4 million upfront from a partnership with Ono Pharmaceutical, with an additional $139 million in potential milestone payments. Revenue for Q4 2022 reached $15.8 million, a significant increase from zero in 2021. However, the net loss for the full year was $62.4 million, up from $39.1 million in 2021. The company anticipates key clinical data releases in the second half of 2023.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, at 10:30 am PT. The presentation will focus on the company's expertise in autoimmune diseases and its lead candidate, EQ101, a tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, currently in a Phase 2 study for alopecia areata. Management will also be available for one-on-one meetings. A live webcast will be accessible on the company's website, with a replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ) has announced positive results from its EQUATE study on Itolizumab, a targeted therapy for acute graft-versus-host disease (aGVHD). The presentation at the American Society of Transplantation and Cellular Therapy showed high clinical response rates with a 70% reduction in steroid use at Day 29 and a remarkable 99% taper at Day 169. These findings suggest potential for Itolizumab as a first-line treatment in severe aGVHD, with the initiation of the pivotal Phase 3 EQUATOR study.
Dr. Koreth emphasized the significance of these results, considering the lack of approved first-line treatments for aGVHD.
Equillium, Inc. (NASDAQ: EQ) announced its participation in the SVB Securities Global Biopharma Conference on February 14 at 10:00 am PT. The presentation will cover the recent partnership with Ono Pharmaceuticals and details on its multi-cytokine inhibitor platform, including EQ101 for alopecia areata and EQ102 for celiac disease. Management will also discuss upcoming catalysts and will be available for one-on-one meetings. The webcast can be accessed via the Investor Relations section of Equillium’s website, and a replay will be available for 90 days.
Equillium, Inc. (Nasdaq: EQ) announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings, taking place from February 15-19, 2023, in Orlando, Florida. The presentation, titled "Final Safety and Efficacy Results from EQUATE," details the promising findings of a Phase 1b study of itolizumab for treating newly diagnosed acute graft-versus-host disease (aGVHD).
The study shows significant outcomes, including long-term follow-ups up to one year. Following these results, Equillium has initiated EQUATOR, a Phase 3 study to evaluate itolizumab as a potential first-line treatment.
